Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased 2 Percent to $1.14
07.28.2008
|
Second Quarter 2008 GAAP Earnings Per Share Decreased 3 percent to $0.87
Full Year Revenue Guidance Raised from $14.2 Billion - $14.6 Billion to $14.6 Billion - $14.9 Billion
Full Year Adjusted EPS Guidance Raised from $4.00 - $4.30 to $4.25 - $4.45
THOUSAND OAKS, Calif., Jul 28, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.14 for the second quarter of 2008, an increase of 2 percent compared to $1.12 for the second quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, decreased 2 percent to $1,235 million in the second quarter of 2008 compared to $1,265 million in the second quarter of 2007. Stock option expense on a per share basis totaled 1 cent and 3 cents for the second quarter of 2008 and 2007, respectively.
Total revenue increased 1 percent during the second quarter of 2008 to $3,764 million versus $3,728 million in the second quarter of 2007.
Adjusted EPS and adjusted net income for the second quarter 2008 and 2007 exclude, for the applicable periods, stock option expense, loss accruals for certain legal proceedings, certain expenses related to acquisitions, restructuring charges and certain other items. These expenses and other items are itemized on the attached reconciliation tables. Adjusted EPS including the impact of stock option expense are also itemized in the notes to the attached reconciliation tables.
Calculated in accordance with United States (U.S.) Generally Accepted Accounting Principles (GAAP), Amgen's GAAP EPS were $0.87 in the second quarter of 2008, a 3 percent decrease compared to $0.90 in the same quarter last year. GAAP net income decreased 8 percent to $941 million in the second quarter of 2008 from $1,019 million in the second quarter of 2007.
"Our business showed good stability through the first half of the year, giving us confidence to increase our previously issued guidance on a full year basis," said Kevin Sharer, chairman and chief executive officer. "We are very pleased with the denosumab Phase 3 results in postmenopausal osteoporosis from the '216 study and are looking forward to presenting these data in detail at a scientific conference this fall. We also expect a number of important events in the second-half of the year including a review of all registration-enabling studies completed so far with denosumab and launch of Nplate," concluded Sharer.
Product Sales Performance
During the second quarter, total product sales increased 2 percent to $3,692 million from $3,604 million in the second quarter of 2007. Sales in the U.S. totaled $2,843 million, a decrease of 1 percent versus $2,879 million in the second quarter of 2007. International sales increased 17 percent to $849 million versus $725 million for the second quarter of 2007. Changes in foreign exchange positively impacted second quarter 2008 sales by $93 million. Excluding the impact of foreign exchange, total product sales were relatively unchanged and international product sales increased 4 percent.
Worldwide sales of Aranesp(R) (darbepoetin alfa) decreased 13 percent to $825 million in the second quarter of 2008 versus $949 million during the second quarter of 2007. This decline was principally driven by U.S. Aranesp sales, which were $427 million in the second quarter of 2008 versus $578 million in the second quarter of the prior year, a decrease of 26 percent. This decline reflects the negative impact on demand, primarily in the supportive cancer care setting, from regulatory and reimbursement changes which principally occurred in the second half of 2007. International Aranesp sales increased 7 percent to $398 million versus $371 million in the second quarter of 2007 due to changes in foreign exchange which positively impacted second quarter 2008 sales by approximately $46 million, partially offset by pricing pressure and ESA (Erythropoiesis Stimulating Agent) dosing conservatism. Excluding the impact of foreign exchange, worldwide product sales decreased 18 percent and international product sales decreased 5 percent.
Sales of EPOGEN(R) (Epoetin alfa) were relatively unchanged at $622 million in the second quarter of 2008 versus $624 million in the second quarter of 2007. The increase in demand due to patient population growth was offset primarily due to a reduction in dose / utilization due to ESA label changes and implementation of the Erythropoietin Monitoring Policy (EMP).
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim) increased 15 percent to $1,201 million in the second quarter of 2008 versus $1,041 million for the second quarter of 2007, driven primarily by increased demand for Neulasta. Combined sales of Neulasta and NEUPOGEN in the U.S. were $869 million in the second quarter of 2008 versus $773 million in the second quarter of 2007, an increase of 12 percent primarily reflecting an increase in demand for Neulasta. This increase in demand was principally driven by an increase in the average net sales price and to a lesser extent an increase in units, which we believe was driven by customer stocking. Combined international sales increased 24 percent to $332 million in the second quarter of 2008 versus $268 million for the same quarter in the prior year. This growth reflects changes in foreign exchange which positively impacted second quarter 2008 combined international sales by approximately $36 million, as well as increased demand driven by the continued conversion from NEUPOGEN to Neulasta. Excluding the impact of foreign exchange, combined worldwide product sales increased 12 percent and international product sales increased 10 percent.
Sales of Enbrel(R) (etanercept) increased 2 percent in the second quarter to $841 million versus $823 million during the same period in 2007. Sales growth was driven by higher demand due to increases in both average net sales price and patients, partially offset by unfavorable changes in wholesaler inventory levels. ENBREL sales growth in the second quarter was affected by share declines in the U.S. versus the second quarter of 2007 due to increased competitive activity. However, sales growth continued in both rheumatology and dermatology, and ENBREL continues to maintain a leading position in both segments.
Worldwide sales of Sensipar(R) (cinacalcet HCl) increased 39 percent to $150 million in the second quarter of 2008 versus $108 million during the second quarter of 2007. This growth was principally driven by demand, primarily due to segment penetration.
Vectibix(R) (panitumumab) sales for the second quarter were $32 million as compared to $45 million in the second quarter of 2007. This decrease was driven by lower U.S. demand.
Operating Expense Analysis on an Adjusted Basis
Cost of sales decreased 6 percent to $512 million in the second quarter of 2008 versus $546 million in the second quarter of 2007. This decrease was primarily driven by lower cost ENBREL and lower inventory reserves. The Company expects full year 2008 adjusted Cost of Sales expense to decrease slightly as a percent of sales versus 2007.
Research & Development (R&D) expenses of $779 million in the second quarter of 2008 were relatively unchanged year over year versus $777 million in the second quarter of 2007. The benefits derived from licensing transactions with Daiichi Sankyo and Takeda in Japan, lower clinical trial costs and lower staff related and other related expense resulting from the 2007 restructuring program were offset by the $100 million upfront payment associated with the Kyowa Hakko collaboration. The Company expects full year 2008 adjusted R&D expense dollars to be similar to 2007.
Selling, General & Administrative (SG&A) expenses increased 6 percent to $894 million in the second quarter of 2008 versus $840 million in the second quarter of 2007 reflecting higher Wyeth profit share expenses and to a lesser extent, higher depreciation and other related expenses associated with placing our Enterprise Resource Planning system in service this quarter. Wyeth profit share expenses increased 13 percent to $283 million in the second quarter of 2008 versus $250 million in the second quarter of 2007. Excluding Wyeth profit share, SG&A expenses in the second quarter of 2008 increased 4 percent versus the same quarter last year. The Company expects 2008 adjusted SG&A expense dollars excluding Wyeth profit share expenses to be slightly higher versus 2007.
During the second quarter of 2008, Amgen repurchased approximately 33 million shares of its common stock at a total cost of $1.5 billion. The Company currently has $4.9 billion remaining under its authorized stock repurchase program. Average diluted shares for adjusted EPS in the second quarter of 2008 were 1,080 million versus 1,132 million in the second quarter of 2007.
Capital expenditures for the second quarter of 2008 were approximately $165 million versus $402 million in the second quarter of 2007. Worldwide cash and marketable securities were $8.5 billion and debt was $11.2 billion at the end of the second quarter of 2008.
2008 Revenue and EPS Guidance Raised
The Company is raising its revenue guidance range from the previously provided range of $14.2 billion to $14.6 billion to an increased range of $14.6 billion to $14.9 billion. The Company is also raising its 2008 adjusted EPS guidance range from the prior range of $4.00 to $4.30 to an increased range of $4.25 to $4.45, excluding stock option expense and certain other expenses, based upon sales momentum and lower operating expense due to continuing efficiencies.
Second Quarter Product and Pipeline Update
The Company provided updates on selected products and late-stage clinical programs.
Aranesp: The Company noted that it continues to work closely with regulatory agencies to complete label revisions.
ENBREL: The Company announced that, on July 24, 2008, it received notification from the FDA through a Complete Response letter that they would like additional information to support the use of ENBREL in pediatric patients with moderate to severe plaque psoriasis. Amgen continues to work with the FDA to provide information to address additional questions related to the supplemental biologics license application (sBLA), and cannot speculate on the timing of the FDA's response.
Vectibix: The Company announced that the Phase 2 STEPP study (Skin Toxicity Evaluation Protocol with Panitumumab) showed that preemptive treatment reduced the incidence rate of skin toxicities without additional side effects.
Nplate(TM) (romiplostim): The Company announced that it continues to work with FDA to assist in the completion of the review process. Nplate is under review for the treatment of thrombocytopenia in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Denosumab: The Company announced that its Phase 3 pivotal PMO fracture study met primary and all secondary endpoints. Treatment with denosumab resulted in a statistically significant reduction in the incidence of new vertebral fractures compared to placebo. Patients receiving denosumab experienced a statistically significant reduction in the incidence of new non-vertebral and hip fractures (secondary endpoints). The incidence and types of adverse and serious adverse events, including serious infections and neoplasms, were similar between the denosumab and placebo groups.
The Company announced that the Phase 3 study for the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer met the bone mineral density primary endpoint. Patients receiving denosumab experienced less than half the incidence of new vertebral fractures (a secondary endpoint) compared with the placebo arm, a statistically significant finding. The incidence and types of adverse events were similar between the denosumab and placebo arms. In addition, the Company announced that the Phase 3 study for the prevention of bone metastases in men with prostate cancer completed enrollment.
For more product information or the full prescribing information, please refer to the Amgen Web site at www.amgen.com.
As previously announced, the Company has posted in the Investors section of the Company's Web site (www.amgen.com/investors) a slide presentation related to its second quarter financial results conference call, scheduled for 2 p.m. Pacific Time today. The conference call will be broadcast over the Internet and can also be found on Amgen's Web site at the above web address.
Non-GAAP Financial Measures
Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP basis) for the three and six months ended June 30, 2008 and 2007. The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with U.S. GAAP.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
Forward-Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2007, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.
Amgen Inc.
Condensed Consolidated Statements of Income and
Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)
Three Months Ended
June 30, 2008
-----------------------------
GAAP Adjustments "Adjusted"
-----------------------------
Revenues:
Product sales $3,692 $ - $3,692
Other revenues 72 - 72
------ -------- ----------
Total revenues 3,764 - 3,764
------ -------- ----------
Operating expenses:
Cost of sales (excludes amortization
of acquired intangible assets
presented below) 515 (3)(a) 512
Research and development 809 (11)(a) 779
(1)(b)
(18)(c)
Selling, general and administrative 904 (10)(a) 894
Amortization of intangible assets 73 (73)(d) -
Other 284 (21)(b) -
(263)(e)
------ -------- ----------
Total operating expenses 2,585 (400) 2,185
------ -------- ----------
Operating income 1,179 400 1,579
Interest and other income, net 9 - 9
------ -------- ----------
Income before income taxes 1,188 400 1,588
Provision for income taxes 247 106 (j) 353
------ -------- ----------
Net income $ 941 $ 294 $1,235
====== ======== ==========
Earnings per share:
Basic $ 0.87 $ 1.15
Diluted (m) $ 0.87 $ 1.14(a)
Average shares used in calculation
of earnings per share:
Basic 1,078 1,078
Diluted (m) 1,081 1,080(a)
Three Months Ended
June 30, 2007
-----------------------------
GAAP Adjustments "Adjusted"
-----------------------------
Revenues:
Product sales $3,604 $ - $3,604
Other revenues 124 - 124
------ -------- ----------
Total revenues 3,728 - 3,728
------ -------- ----------
Operating expenses:
Cost of sales (excludes amortization
of acquired intangible assets
presented below) 558 (7)(a) 546
(1)(f)
(4)(g)
Research and development 817 (21)(a) 777
(18)(c)
(1)(h)
Selling, general and administrative 860 (20)(a) 840
Amortization of intangible assets 74 (74)(d) -
Other 289 (289)(b) -
------ -------- ----------
Total operating expenses 2,598 (435) 2,163
------ -------- ----------
Operating income 1,130 435 1,565
Interest and other income, net 7 - 7
------ -------- ----------
Income before income taxes 1,137 435 1,572
Provision for income taxes 118 92 (k) 307
97 (l)
------ -------- ----------
Net income $1,019 $ 246 $1,265
====== ======== ==========
Earnings per share:
Basic $ 0.90 $ 1.12
Diluted (m) $ 0.90 $ 1.12(a)
Average shares used in calculation
of earnings per share:
Basic 1,129 1,129
Diluted (m) 1,134 1,132(a)
(a) - (m) See explanatory notes on the following pages.
Amgen Inc.
Condensed Consolidated Statements of Income and
Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)
Six Months Ended
June 30, 2008
------------------------------
GAAP Adjustments "Adjusted"
------------------------------
Revenues:
Product sales $7,229 $ - $7,229
Other revenues 148 - 148
------ -------- ----------
Total revenues 7,377 - 7,377
Operating expenses:
Cost of sales (excludes
amortization of acquired
intangible assets presented below) 1,061 (6)(a) 1,054
(1)(b)
Research and development 1,503 (23)(a) 1,440
(3)(b)
(36)(c)
(1)(h)
Selling, general and administrative 1,778 (23)(a) 1,756
1 (b)
Amortization of intangible assets 147 (147)(d) -
Other items 294 (31)(b) -
(263)(e)
------ -------- ----------
Total operating expenses 4,783 (533) 4,250
Operating income 2,594 533 3,127
Interest and other income, net 31 - 31
------ -------- ----------
Income before income taxes 2,625 533 3,158
Provision for income taxes 548 157 (j) 705
------ -------- ----------
Net income $2,077 $ 376 $2,453
====== ======== ==========
Earnings per share:
Basic $ 1.92 $ 2.27
Diluted (m) $ 1.91 $ 2.26(a)
Average shares used in calculation
of earnings per share:
Basic 1,083 1,083
Diluted (m) 1,086 1,085(a)
Six Months Ended
June 30, 2007
------------------------------
GAAP Adjustments "Adjusted"
------------------------------
Revenues:
Product sales $7,169 $ - $7,169
Other revenues 246 - 246
------ -------- ----------
Total revenues 7,415 - 7,415
Operating expenses:
Cost of sales (excludes
amortization of acquired
intangible assets presented below) 1,150 (8)(a) 1,105
(7)(f)
(30)(g)
Research and development 1,668 (48)(a) 1,580
(37)(c)
(3)(h)
Selling, general and administrative 1,630 (42)(a) 1,588
Amortization of intangible assets 148 (148)(d) -
Other items 289 (289)(b) -
------ -------- ----------
Total operating expenses 4,885 (612) 4,273
Operating income 2,530 612 3,142
Interest and other income, net 1 51 (i) 52
------ -------- ----------
Income before income taxes 2,531 663 3,194
Provision for income taxes 401 92 (k) 659
166 (l)
------ -------- ----------
Net income $2,130 $ 405 $2,535
====== ======== ==========
Earnings per share:
Basic $ 1.86 $ 2.21
Diluted (m) $ 1.84 $ 2.20(a)
Average shares used in calculation
of earnings per share:
Basic 1,147 1,147
Diluted (m) 1,155 1,152(a)
(a) - (m) See explanatory notes on the following pages.
Amgen Inc.
Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)
(a) To exclude the impact of stock option expense recorded in
accordance with Statement of Financial Accounting Standards
("SFAS") No. 123R. For the three and six months ended June 30,
2008 and 2007, the total pre-tax expense for employee stock
options in accordance with SFAS No. 123R was $24 million and $48
million, respectively, and $52 million and $98 million,
respectively.
"Adjusted" diluted EPS including the impact of stock option
expense for the three and six months ended June 30, 2008 and
2007 was as follows:
Three Months Ended Six Months Ended
June 30, June 30,
----------------- ----------------
2008 2007 2008 2007
----------------- ----------------
"Adjusted" diluted EPS,
excluding stock option expense $ 1.14 $ 1.12 $ 2.26 $ 2.20
Impact of stock option
expense (net of tax) (0.01) (0.03) (0.03) (0.06)
-------- ------- -------- -------
"Adjusted" diluted EPS,
including stock option expense $ 1.13 $ 1.09 $ 2.23 $ 2.14
======== ======= ======== =======
(b) To exclude the following restructuring (expenses)/recoveries
associated with our restructuring plan announced in August 2007,
as follows (in millions):
Separation Asset Other Total
Costs (1) Impairment (3)
(2)
--------- ---------- ----- ------
Three Months Ended June 30, 2008
--------------------------------
Research and development (R&D) $(1) $ - $ - $ (1)
Other - (12) (9) (21)
--------- ---------- ----- ------
$(1) $ (12) $ (9) $ (22)
========= ========== ===== ======
Three Months Ended June 30, 2007
--------------------------------
Other $(3) $(286) $ - $(289)
--------- ---------- ----- ------
$(3) $(286) $ - $(289)
========= ========== ----- ======
Six Months Ended June 30, 2008
--------------------------------
Cost of sales (excluding
amortization of intangible
assets) $ - $ (1) $ - $ (1)
R&D (3) - - (3)
Selling, general and
administrative - - 1 1
Other (4) (14) (13) (31)
--------- ---------- ----- ------
$(7) $ (15) $(12) $ (34)
========= ========== ===== ======
Six Months Ended June 30, 2007
-------------------------------
Other $(3) $(286) $ - $(289)
--------- ---------- ----- ------
$(3) $(286) $ - $(289)
========= ========== ----- ======
(1) Severance and other related costs.
(2) Asset impairment charges incurred in connection with the
rationalization of our worldwide manufacturing operations
and, to a lesser degree, moderation of the expansion of our
research facilities.
(3) Principally related to loss accruals for leases for certain
facilities that will not be used in our business.
(c) To exclude the ongoing, non-cash amortization of the R&D
technology intangible assets acquired with the acquisition of
Abgenix, Inc. ("Abgenix") and Avidia, Inc. ("Avidia").
(d) To exclude the ongoing, non-cash amortization of acquired product
technology rights, primarily ENBREL, related to the Immunex
Corporation ("Immunex") acquisition.
(e) To exclude loss accruals for settlements of certain commercial
legal proceedings.
(f) To exclude merger related expenses incurred due to the Abgenix
acquisition, primarily related to incremental costs associated
with recording inventory acquired at fair value which is in
excess of our manufacturing cost.
(g) To exclude the impact of writing-off the cost of a semi-completed
manufacturing asset that will not be used due to a change in
manufacturing strategy.
(h) To exclude for the applicable periods merger related expenses
incurred due to the Alantos Pharmaceutical Holding, Inc., and
Tularik Inc. acquisitions, primarily related to incremental costs
associated with retention. Substantially all related amounts have
been incurred.
(i) To exclude the pro rata portion of the deferred financing and
related costs that were immediately charged to interest expense
as a result of certain holders of our convertible notes due in
2032 exercising their March 1, 2007 put option and the related
convertible notes being repaid in cash.
(j) To reflect the tax effect of the above adjustments for 2008,
excluding certain of the restructuring charges (see (b) above)
and certain of the loss accruals for settlements of commercial
legal proceedings (see (e) above).
(k) To exclude the income tax benefit recognized as the result of
resolving certain non-routine transfer pricing issues with the
Internal Revenue Service ("IRS") for prior periods.
(l) To reflect the tax effect of the above adjustments for 2007,
excluding (1) the tax benefit recognized as a result of resolving
certain transfer pricing issues with the IRS (see (k) above), (2)
certain of the restructuring charges (see (b) above) and (3) the
write-off of the cost of a semi-completed manufacturing asset
(see (g) above).
(m) The following table presents the computations for GAAP and
"Adjusted" diluted earnings per share, computed under the
treasury stock method. "Adjusted" earnings per share presented
below excludes stock option expense:
Three Months Ended Three Months Ended
June 30, 2008 June 30, 2007
------------------- -------------------
GAAP "Adjusted" GAAP "Adjusted"
------------------- -------------------
Income (Numerator):
Net income for basic and
diluted EPS $ 941 $1,235 $1,019 $1,265
======= ======= ======== =======
Shares (Denominator):
Weighted-average shares
for basic EPS 1,078 1,078 1,129 1,129
Effect of dilutive
securities 3 2 (A) 5 3 (A)
------- ------- -------- -------
Weighted-average shares
for diluted EPS 1,081 1,080 1,134 1,132
======= ======= ======== =======
Diluted earnings per share $ 0.87 $ 1.14 $ 0.90 $ 1.12
======= ======= ======== =======
Six Months Ended Six Months Ended
June 30, 2008 June 30, 2007
------------------- -------------------
GAAP "Adjusted" GAAP "Adjusted"
------------------- -------------------
Income (Numerator):
Net income for basic and
diluted EPS $2,077 $2,453 $2,130 $2,535
======= ======= ======== =======
Shares (Denominator):
Weighted-average shares
for basic EPS 1,083 1,083 1,147 1,147
Effect of dilutive
securities 3 2 (A) 8 5 (A)
------- ------- -------- -------
Weighted-average shares
for diluted EPS 1,086 1,085 1,155 1,152
======= ======= ======== =======
Diluted earnings per share $ 1.91 $ 2.26 $ 1.84 $ 2.20
======= ======= ======== =======
(A) Dilutive securities used to compute "Adjusted" diluted earnings
per share for the three and six months ended June 30, 2008 and
2007 were computed exclusive of the methodology used to determine
dilutive securities under SFAS No. 123R.
Amgen Inc.
Product Sales Detail by Product and Geographic Region
(In millions)
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
------------------ ----------------
2008 2007 2008 2007
------------------ ----------------
Aranesp(R) - U.S $ 427 $ 578 $ 832 $1,232
Aranesp(R) - International 398 371 754 737
EPOGEN(R) - U.S 622 624 1,176 1,249
Neulasta(R) - U.S 648 573 1,217 1,146
NEUPOGEN(R) - U.S 221 200 444 404
Neulasta(R) - International 214 161 401 307
NEUPOGEN(R) - International 118 107 225 202
Enbrel(R) - U.S 789 777 1,693 1,470
Enbrel(R) - International 52 46 99 83
Sensipar(R) - U.S 102 76 195 153
Sensipar(R) - International 48 32 88 60
Vectibix(R) - U.S 25 45 57 96
Vectibix(R) - International 7 - 9 -
Other product sales - U.S 9 6 18 13
Other product sales -
International 12 8 21 17
----------- ------ --------- ------
Total product sales $3,692 $3,604 $7,229 $7,169
=========== ====== ========= ======
U.S $2,843 $2,879 $5,632 $5,763
International 849 725 1,597 1,406
----------- ------ --------- ------
Total product sales $3,692 $3,604 $7,229 $7,169
=========== ====== ========= ======
Amgen Inc.
Condensed Consolidated Balance Sheets - GAAP
(In millions)
(Unaudited)
June 30, December 31,
2008 2007
-------- ------------
Assets
Current assets:
Cash, cash equivalents and marketable
securities $ 8,483 $ 7,151
Trade receivables, net 2,331 2,101
Inventories 2,134 2,091
Other current assets 1,579 1,698
-------- ------------
Total current assets 14,527 13,041
Property, plant and equipment, net 5,968 5,941
Intangible assets, net 3,176 3,332
Goodwill 11,338 11,240
Other assets 1,052 1,085
-------- ------------
Total assets $36,061 $34,639
======== ============
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities $ 4,429 $ 4,179
Current portion of other long-term debt 1,000 2,000
-------- ------------
Total current liabilities 5,429 6,179
Deferred tax liabilities 381 480
Convertible notes 5,081 5,080
Other long-term debt 5,094 4,097
Other non-current liabilities 1,543 934
Stockholders' equity 18,533 17,869
-------- ------------
Total liabilities and stockholders' equity $36,061 $34,639
======== ============
Shares outstanding 1,057 1,087
Amgen Inc.
Reconciliation of "Adjusted" Earnings Per Share Guidance to GAAP
Earnings Per Share Guidance for the Year Ending December 31, 2008
2008
----------------
"Adjusted" earnings per share guidance $ 4.25 - $ 4.45
Known adjustments to arrive at GAAP earnings:
Legal settlements (a) (0.19)
Amortization of acquired intangible assets,
product technology rights (b) (0.17)
Stock option expense (c) (0.06)- (0.08)
Restructuring costs (d) (0.02)- (0.05)
Amortization of acquired intangible assets, R&D
technology rights (e) (0.04)
-------- -------
GAAP earnings per share guidance $ 3.72 - $ 3.97
======== =======
(a) To exclude loss accruals for settlements of certain commercial
legal proceedings.
(b) To exclude the ongoing, non-cash amortization of acquired product
technology rights, primarily ENBREL, related to the Immunex
acquisition.
(c) To exclude stock option expense associated with SFAS No. 123R.
(d) To exclude restructuring related costs.
(e) To exclude the ongoing, non-cash amortization of the R&D
technology intangible assets acquired with the Abgenix and Avidia
acquisitions.
SOURCE: Amgen
Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)